Turning the Question Around: How Can Patients Support Precision Medicine?
Time: 4:30 pm
day: Track B - Day 2 pm
• The development of clinically meaningful and patientrelevant biosignatures can be a long and cumbersome process. When we include patients’ input from the start it may become easier and faster
• The objective of predicting responders and nonresponders may not always require the most complex and comprehensive biosignature but ultimately the optimised benefit-risk needs to be demonstrated to regulators, physicians and patients
• Examples from disease areas like heart failure, atherosclerotic cardiovascular disease, multiple sclerosis and psoriasis will illustrate specific precision medicine opportunities and challenges
• The future is precision medicine, let’s make sure we don’t lose common sense and the human touch